Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and ...

Biotech veteran brings 20+ years of operations, facility design and manufacturing expertise Eric Hanson Industry veteran named Senior Director of Life Sciences at CRB Kansas City, Mo., Aug. 14, 2025 ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...